Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita

National Center for Research Resources (NCRR)

Status and phase: Completed; Phase 2

Conditions: Epidermolysis Bullosa Acquisita

Treatments: Drug: methoxsalen

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00004359

NU-511

199/11928

Details and patient eligibility

About

OBJECTIVES: I. Evaluate immunomodulation with extracorporeal photochemotherapy (ECP) in patients with epidermolysis bullosa acquisita.

II. Investigate the effect of ECP on lymphocyte activity.

Full description

PROTOCOL OUTLINE: Oral methoxsalen (8-MOP) is administered 90 minutes prior to leukapheresis. Blood mononuclear cells are exposed to ultraviolet A light for 3 hours, then returned to the patient. The process is repeated on 2 successive days.

Patients are re-treated every 3 to 4 weeks for a total of 6 treatments or until the skin has cleared.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Active epidermolysis bullosa acquisita